The LiquiDx project made a significant step forward in the innovation of cfRNA-based liquid biopsies, combining next-generation sequencing, bioinformatics, and precision medicine solutions to create a cutting-edge diagnostic platform for use in clinical settings. These developments highlight the consortium’s commitment to advancing early cancer detection and accelerating the translation of new technologies into accessible clinical tools to improve patient outcomes. The main outcomes of LiquiDx are also planned to be shared with the scientific community in a scientific publication.
Flomics Biotech, Leitat and BBSSPA acknowledge the financial support received for the LiquiDx project, associated with the action with action file number CPP2021-008897, which was financed by MCIN/AEI/10.13039/501100011033 and by the European Union “NextGenerationEU/PRTR”, through the 2021 call for public-private collaboration projects of the Agencia Estatal de Investigación.